Summary

Although tumor necrosis factor inhibitors (TNFis) have been shown to be effective in the treatment of rheumatoid arthritis, little is known about the effect of stopping this therapy in patients with stable low disease activity, particularly with respect to the likelihood of disease flare, and whether TNFis can be restarted effectively and safely. This article looks at the multicenter, open-label, randomized, Potential Optimalization of (Expediency) and Effectiveness of TNF-blockers trial [POET; NTR3112].